Alexion Pharmaceuticals Inc., of New Haven, Conn., said researchers presented data showing children with perinatal- and infantile-onset hypophosphatasia (HPP) treated with Strensiq (asfotase alfa) had statistically significant improvements in bone healing as assessed radiographically, which were sustained through 3.5 years of treatment.